Our objective was to evaluate an open-label. multicenter. single-arm study to appraise whether amrubicin therapy improves patients with refractory small-cell lung cancer in Chinese clinical study. Patients (n=95) with refractory small-cell lung cancer received 3 consecutive days amrubicin therapy for 21 days. https://thebrickes.shop/product-category/shipping-fee/